Press coverage about Amyris (NASDAQ:AMRS) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amyris earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 44.5650822950424 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:

Several research analysts have commented on AMRS shares. Zacks Investment Research downgraded Amyris from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. HC Wainwright set a $15.00 price objective on Amyris and gave the stock a “buy” rating in a report on Friday, August 11th. Cowen and Company set a $4.00 price objective on Amyris and gave the stock a “hold” rating in a report on Thursday, August 17th. Finally, ValuEngine upgraded Amyris from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $20.69.

Amyris (AMRS) traded up 3.36% on Friday, reaching $3.38. The company’s stock had a trading volume of 269,126 shares. The firm’s market capitalization is $127.11 million. Amyris has a 52 week low of $1.86 and a 52 week high of $18.15. The company has a 50 day moving average of $2.99 and a 200 day moving average of $4.46.

Amyris (NASDAQ:AMRS) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.35). The firm had revenue of $25.68 million during the quarter, compared to analyst estimates of $23.68 million. During the same quarter in the prior year, the company earned ($0.06) earnings per share. The company’s revenue for the quarter was up 167.5% on a year-over-year basis. On average, analysts forecast that Amyris will post ($3.42) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Insider Buying and Selling by Quarter for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.